亚洲AV永久无码精品国产精品,精品国产a∨无码一区二区三区 ,亚洲AV成人无码网站天堂网久久,四虎成人久久精品无码,亚洲日韩久久综合中文字幕

#塞利尼索#

0篇內(nèi)容 | 1094人圍觀

關(guān)注話題

話題活躍用戶

#插入話題

插入圖片

最新最熱

[GetTopicListResponse(id=2271434, encodeId=ee6522e1434ef, content=<a href='/topic/show?id=8fe738515a' target=_blank style='color:#2F92EE;'>#B細(xì)胞淋巴瘤#</a> <a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a>, objectTitle=【Cancer Sci】塞利尼索可協(xié)同CD19 CAR-T治療B細(xì)胞淋巴瘤, objectType=article, longId=884592, objectId=aa42884592fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220813/1660373278819_8252897.webp, objectUrl=/article/show_article.do?id=aa42884592fc, replyNumber=0, likeNumber=33, createdTime=2025-06-30, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aa42884592fc, moduleTitle=【Cancer Sci】塞利尼索可協(xié)同CD19 CAR-T治療B細(xì)胞淋巴瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=aa42884592fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211392, encodeId=d023221139264, content=<a href='/topic/show?id=9ad2111e516c' target=_blank style='color:#2F92EE;'>#髓源性抑制細(xì)胞#</a> <a href='/topic/show?id=6e87188525c' target=_blank style='color:#2F92EE;'>#XPO1#</a> <a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a>, objectTitle=Cell Mol Immunol：新研究發(fā)現(xiàn)XPO1蛋白控制腫瘤中髓源性抑制細(xì)胞的免疫抑制功能, objectType=article, longId=831525, objectId=0cc683152575, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240623/1719144313361_2185383.png, objectUrl=/article/show_article.do?id=0cc683152575, replyNumber=0, likeNumber=69, createdTime=2024-06-24, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209746, encodeId=5eaa2209e462d, content=<a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a> <a href='/topic/show?id=c8431154e5fb' target=_blank style='color:#2F92EE;'>#2024 EHA#</a>, objectTitle=2024 EHA｜中國之聲：塞利尼索重磅成果一覽, objectType=article, longId=829591, objectId=f3d382959124, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240606/1717679081671_8624274.png, objectUrl=/article/show_article.do?id=f3d382959124, replyNumber=0, likeNumber=111, createdTime=2024-06-13, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f3d382959124, moduleTitle=2024 EHA｜中國之聲：塞利尼索重磅成果一覽, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f3d382959124)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188739, encodeId=fb612188e39c8, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多發(fā)性骨髓瘤#</a> <a href='/topic/show?id=a4671201218' target=_blank style='color:#2F92EE;'>#MM#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#達(dá)雷妥尤單抗#</a> <a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a>, objectTitle=【Haematologica】塞利尼索+達(dá)雷妥尤單抗+Vd治療RRMM的II期研究, objectType=article, longId=814080, objectId=882f81408000, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=882f81408000, replyNumber=0, likeNumber=138, createdTime=2024-02-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=882f81408000, moduleTitle=【Haematologica】塞利尼索+達(dá)雷妥尤單抗+Vd治療RRMM的II期研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=882f81408000)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理員

多發(fā)性骨髓瘤 MM 地塞米松達(dá)雷妥尤單抗塞利尼索

2024-02-22發(fā)表于上海

梅斯管理員 (審核中...)

前往app查看評論內(nèi)容

#B細(xì)胞淋巴瘤# #塞利尼索#

【Cancer Sci】塞利尼索可協(xié)同CD19 CAR-T治療B細(xì)胞淋巴瘤

2025-06-30發(fā)表于上海

梅斯管理員 (審核中...)

前往app查看評論內(nèi)容

#髓源性抑制細(xì)胞# #XPO1# #塞利尼索#

2024-06-24發(fā)表于上海

梅斯管理員 (審核中...)

前往app查看評論內(nèi)容

#塞利尼索# #2024 EHA#

2024 EHA｜中國之聲：塞利尼索重磅成果一覽

2024-06-13發(fā)表于上海

梅斯管理員 (審核中...)

前往app查看評論內(nèi)容

#多發(fā)性骨髓瘤# #MM# #地塞米松# #達(dá)雷妥尤單抗# #塞利尼索#

【Haematologica】塞利尼索+達(dá)雷妥尤單抗+Vd治療RRMM的II期研究

2024-02-22發(fā)表于上海

科室
- - 訂閱+
  - 更多科室
工具
服務(wù)

<noscript id="k3sny"></noscript>